Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
- 1 September 1999
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (9) , 2639
- https://doi.org/10.1200/jco.1999.17.9.2639
Abstract
PURPOSE: Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized ant...Keywords
This publication has 24 references indexed in Scilit:
- The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A reviewGene, 1995
- The biology of erbB-2/nue/HER-2 and its role in cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1994
- Growth Factors and CancerScience, 1991
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.Proceedings of the National Academy of Sciences, 1987
- erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 CellsScience, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- The Product of the Human c- erb B-2 Gene: a 185-Kilodalton Glycoprotein with Tyrosine Kinase ActivityScience, 1986
- p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.Molecular and Cellular Biology, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985